Meteospasmyl

Alverine citrate, the active ingredient in Meteospasmyl, is an antispasmodic presented as an oral tablet for oral use. It relaxes gastrointestinal smooth muscle and, together with simeticone, helps relieve abdominal pain, intestinal spasm and excess gas in adults, particularly in functional bowel disorders.

GNH USA supplies Meteospasmyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meteospasmyl, an antispasmodic/antiflatulent, is used to manage gastrointestinal conditions characterized by spasm and gas.

- Abdominal pain: reduces pain by relaxing gut smooth muscle. - Intestinal spasm: alleviates spasm episodes, improving bowel comfort. - Flatulence: simeticone component facilitates gas elimination, decreasing bloating.

Meteospasmyl may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Headache - Dizziness - Diarrhoea

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or swelling - Severe abdominal pain - Unexplained changes in blood pressure

Before using Meteospasmyl, consider the following precautions.

- Medical history: disclose any gastrointestinal, cardiac or hepatic conditions. - Concurrent medications: review for potential interactions, especially other antispasmodics. - Pregnancy and lactation: use only if benefits outweigh risks. - Elderly patients: monitor for increased sensitivity to side effects. - Allergy: avoid if known hypersensitivity to alverine, simeticone or excipients. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Meteospasmyl can interact with other medicines; assess the risk level before co‑administration.

Major Interactions (Avoid): - Other antispasmodics: additive muscle relaxation may cause severe gastrointestinal dysmotility. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - Antacids: may affect alverine absorption. - CYP3A4 substrates: alverine is metabolised by CYP3A4 and could alter levels of drugs such as statins. - Diuretics: possible electrolyte shifts requiring monitoring.